OAB patient satisfaction and improved perception of bladder condition with darifenacin

Ebinger U1, Zinner N2, Koochaki P3, Chandra P4, Egermark M5

Abstract Category

Detrusor Overactivity

Abstract 585
Read by Title
Scientific Non Discussion Abstract Session 20
1. Novartis Pharmaceuticals Corp., East Hanover, NJ, USA, 2. Western Clinical Research Inc., Torrance, CA, USA, 3. Procter and Gamble Pharmaceuticals Corp., Cincinnati, OH, USA, 4. Novartis Healthcare Pvt. Ltd., Madhapur/Hyderabad, India, 5. Novartis Pharma AG, Basel, Switzerland
Links

Abstract

19/04/2024 00:05:04